Page last updated: 2024-08-21

metylperon and risperidone

metylperon has been researched along with risperidone in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (66.67)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Delius-Stute, H; Kurz, A; Rettig, K; Schwalen, S1
Buchkremer, G; Köhnke, MD; Lutz, U; Schott, K; Schwärzler, F; Weller, B; Wiatr, G1
Doblhammer, G; Eriksdotter, M; Garcia-Ptacek, S; Haenisch, B; Johnell, K; Nerius, M1

Other Studies

6 other study(ies) available for metylperon and risperidone

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
[Atypical neuroleptics in dementia. Managing behavioral disorders early and efficiently].
    MMW Fortschritte der Medizin, 2002, Mar-07, Volume: 144, Issue:10

    Topics: Activities of Daily Living; Aged; Alzheimer Disease; Antipsychotic Agents; Butyrophenones; Clinical Trials as Topic; Humans; Risperidone; Social Behavior Disorders; Treatment Outcome

2002
[Treatment of behavioral disorders in dementia with risperidone in psychogeriatric out-patients].
    MMW Fortschritte der Medizin, 2003, Oct-09, Volume: 145 Suppl 3

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Ambulatory Care; Antipsychotic Agents; Butyrophenones; Clinical Trials as Topic; Dementia, Vascular; Dose-Response Relationship, Drug; Female; Humans; Male; Mental Disorders; Multicenter Studies as Topic; Prospective Studies; Risperidone; Treatment Outcome

2003
Cytochrome P450 2D6 dependent metabolization of risperidone is inhibited by melperone.
    European journal of clinical pharmacology, 2006, Volume: 62, Issue:4

    Topics: Adult; Butyrophenones; Cytochrome P-450 CYP2D6 Inhibitors; Humans; Male; Risperidone; Schizophrenia; Sleep Deprivation

2006
The Impact of Antipsychotic Drugs on Long-term Care, Nursing Home Admission, and Death in Dementia Patients.
    The journals of gerontology. Series A, Biological sciences and medical sciences, 2018, 09-11, Volume: 73, Issue:10

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Butyrophenones; Cohort Studies; Dementia; Female; Germany; Haloperidol; Homes for the Aged; Humans; Institutionalization; Long-Term Care; Male; Middle Aged; Nursing Homes; Proportional Hazards Models; Quetiapine Fumarate; Risk Factors; Risperidone

2018
chemdatabank.com